Adage Capital Partners’s Silence Therapeutics SLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.42M Buy
+130,000
New +$1.58M ﹤0.01% 917
2024
Q4
– Sell
-320,000
Closed -$5.82M – 954
2024
Q3
$5.82M Sell
320,000
-280,000
-47% -$5.21M 0.01% 698
2024
Q2
$11.4M Hold
600,000
– – 0.02% 573
2024
Q1
$13M Buy
+600,000
New +$13M 0.02% 552
2023
Q1
– Sell
-700,000
Closed -$10.7M – 984
2022
Q4
$10.7M Hold
700,000
– – 0.03% 615
2022
Q3
$7.02M Buy
700,000
+135,000
+24% +$1.42M 0.02% 727
2022
Q2
$6.7M Buy
565,000
+15,000
+3% +$182K 0.02% 765
2022
Q1
$10.4M Hold
550,000
– – 0.02% 681
2021
Q4
$13.1M Buy
550,000
+105,556
+24% +$2.44M 0.02% 616
2021
Q3
$9.16M Hold
444,444
– – 0.02% 714
2021
Q2
$11.6M Hold
444,444
– – 0.02% 651
2021
Q1
$10.2M Buy
+444,444
New +$10.8M 0.02% 666

Other funds holding SLN

Adage Capital Partners's SLN Position: Q3 2026 in Review

Adage Capital Partners opened a new position in Silence Therapeutics (SLN) in Q3 2026: 130,000 shares worth $1.42M. The stake represents ﹤0.01% of the portfolio and ranks #917 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in SLN as recently as Q3 2024.

Adage Capital Partners first reported a position in SLN in Q1 2021 and has held it in 12 quarters since. The position peaked at $13.1M in Q4 2021. 92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Adage Capital Partners held 130,000 shares of Silence Therapeutics worth $1.42M as of Q3 2026.
  • Silence Therapeutics was a new Adage Capital Partners position in Q3 2026.
  • Silence Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q3 2026, its #917 holding.
  • Adage Capital Partners first reported a position in Silence Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • Adage Capital Partners's Silence Therapeutics position peaked at $13.1M in Q4 2021.
  • 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.